Peiró, G <br/><br/>
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.  [electronic resource] 

 -  British journal of cancer  Aug 2014 
 - 689-95 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2014.327  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Breast Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Central Nervous System Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Class I Phosphatidylinositol 3-Kinases<br/>DNA Mutational Analysis<br/>Drug Resistance, Neoplasm<br/>Enzyme Activation<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Receptor, ErbB-2--metabolism<br/>Signal Transduction<br/>Trastuzumab<br/>src-Family Kinases--antagonists & inhibitors